These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17361914)

  • 1. [Localized prostate cancer. What to say to the patient?].
    Coloby P
    Ann Urol (Paris); 2006 Dec; 40 Suppl 2():S18-23. PubMed ID: 17361914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The assessment of pathological PSA values by the general practitioner--observation or intervention?].
    Braun KP; Brookman-Amissah S; May M; Grassmel Y; Hoschke B; Braun V
    Aktuelle Urol; 2009 May; 40(3):171-4. PubMed ID: 19479670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
    Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
    Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
    Adolfsson J
    Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.
    Wilt TJ
    Semin Urol Oncol; 2002 Feb; 20(1):10-7. PubMed ID: 11828353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
    Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
    JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prostate, cancer and lost patients].
    Nau JY
    Rev Med Suisse; 2012 May; 8(343):1186-7. PubMed ID: 22737953
    [No Abstract]   [Full Text] [Related]  

  • 9. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate specific antigen in individual cancer checkups and in therapeutic treatment].
    Recker F
    Ther Umsch; 2006 Feb; 63(2):135-41. PubMed ID: 16514966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
    Khan MA; Carter HB; Epstein JI; Miller MC; Landis P; Walsh PW; Partin AW; Veltri RW
    J Urol; 2003 Dec; 170(6 Pt 1):2274-8. PubMed ID: 14634395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice.
    Wilt TJ; Dahm P
    J Natl Compr Canc Netw; 2015 Dec; 13(12):1566-74. PubMed ID: 26656523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL.
    Terakawa T; Miyake H; Kanomata N; Kumano M; Takenaka A; Fujisawao M
    Urology; 2008 Dec; 72(6):1194-7. PubMed ID: 18829081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer: diagnostic and therapeutic strategies with emphasis on the role of PSA.
    Khauli RB
    J Med Liban; 2005; 53(2):95-102. PubMed ID: 16604995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early management of prostate cancer: how to respond to an elevated PSA?
    Canto EI; Slawin KM
    Annu Rev Med; 2002; 53():355-68. PubMed ID: 11818479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potentially curable prostate cancer patient and the pathways leading to diagnosis and treatment.
    Gjengstø P; Eide J; Frugård J; Bakke A; Høisaeter PA
    Scand J Urol Nephrol; 2004; 38(1):15-8. PubMed ID: 15204421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stratification of prostate-specific antigen level and results of transrectal ultrasonography and digital rectal examination as predictors of positive prostate biopsy.
    Clark TW; Goldenberg L; Cooperberg PL; Wong AD; Singer J
    Can Assoc Radiol J; 1997 Aug; 48(4):252-8. PubMed ID: 9282157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA and the family physician.
    Barkin J
    Can J Urol; 2011 Apr; 18 Suppl():20-3. PubMed ID: 21501547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A performance analysis of the presence of malignant circulating prostate cells as a predictive factor for the detection of prostate cancer in the first, second and third prostate biopsy.
    Murray NP; Reyes E; Tapia P; Badinez L; Orellana N; Fuentealba C; Olivares R; Dueñas R
    Arch Esp Urol; 2013 May; 66(4):335-41. PubMed ID: 23676536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer.
    Porcaro AB; Petrozziello A; Ghimenton C; Migliorini F; Sava T; Caruso B; Romano M; Cavalleri S; Artibani W
    Urol Int; 2014; 93(3):269-78. PubMed ID: 24334919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.